-$0.12 Earnings Per Share Expected for Chromadex Corp (NASDAQ:CDXC) This Quarter

Wall Street brokerages predict that Chromadex Corp (NASDAQ:CDXC) will report ($0.12) earnings per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Chromadex’s earnings. The highest EPS estimate is ($0.10) and the lowest is ($0.13). Chromadex reported earnings per share of ($0.15) during the same quarter last year, which suggests a positive year-over-year growth rate of 20%. The business is expected to issue its next quarterly earnings results on Thursday, August 8th.

On average, analysts expect that Chromadex will report full year earnings of ($0.42) per share for the current fiscal year, with EPS estimates ranging from ($0.47) to ($0.33). For the next year, analysts anticipate that the company will report earnings of ($0.02) per share, with EPS estimates ranging from ($0.14) to $0.19. Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that follow Chromadex.

Chromadex (NASDAQ:CDXC) last issued its earnings results on Thursday, May 9th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.04). The company had revenue of $10.05 million for the quarter, compared to analyst estimates of $9.80 million. Chromadex had a negative net margin of 94.78% and a negative return on equity of 108.84%.



CDXC has been the subject of a number of research reports. Zacks Investment Research lowered shares of Chromadex from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. HC Wainwright set a $7.00 target price on shares of Chromadex and gave the company a “buy” rating in a research note on Tuesday, May 28th. B. Riley reissued a “buy” rating on shares of Chromadex in a research note on Friday, March 8th. Finally, BidaskClub raised shares of Chromadex from a “hold” rating to a “buy” rating in a research note on Thursday, May 9th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $6.00.

Several hedge funds have recently added to or reduced their stakes in CDXC. Tieton Capital Management LLC lifted its stake in shares of Chromadex by 15.1% in the 1st quarter. Tieton Capital Management LLC now owns 1,257,890 shares of the company’s stock valued at $5,271,000 after purchasing an additional 165,425 shares during the last quarter. Sargent Investment Group LLC acquired a new stake in shares of Chromadex in the 4th quarter valued at $355,000. Vanguard Group Inc. lifted its stake in shares of Chromadex by 5.9% in the 3rd quarter. Vanguard Group Inc. now owns 1,572,078 shares of the company’s stock valued at $6,744,000 after purchasing an additional 88,125 shares during the last quarter. Granite Investment Partners LLC lifted its stake in shares of Chromadex by 87.7% in the 1st quarter. Granite Investment Partners LLC now owns 167,689 shares of the company’s stock valued at $702,000 after purchasing an additional 78,373 shares during the last quarter. Finally, Miracle Mile Advisors LLC acquired a new stake in shares of Chromadex in the 1st quarter valued at $272,000. 18.11% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ:CDXC traded up $0.06 during trading on Tuesday, reaching $3.77. 18,884 shares of the company traded hands, compared to its average volume of 133,707. The company has a fifty day simple moving average of $4.29. The firm has a market cap of $210.98 million, a price-to-earnings ratio of -6.11 and a beta of 1.15. Chromadex has a 1-year low of $2.79 and a 1-year high of $5.00. The company has a current ratio of 2.24, a quick ratio of 1.68 and a debt-to-equity ratio of 0.07.

About Chromadex

ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function.

Further Reading: Trading Strategy Examples and Plans

Get a free copy of the Zacks research report on Chromadex (CDXC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.